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Abstract
Background: Crimean-Congo hemorrhagic fever
(CCHF) is a public health problem in many countries.
Chitotriosidase (ChT) is an enzyme secreted by acti-
vated macrophages that catalyzes the hydrolysis of
chitin and chitin-like substrates. The goal of this study
was to assess the relationship between serum ChT
activity and mortality.
Methods: ChT activities on the first day of hospitali-
zation were analyzed in serum from 46 patients
with CCHF and 36 healthy controls. Serum ChT
activities and other clinical and laboratory parameters
for patients with non-fatal and fatal CCHF were
compared.
Results: The median ChT activity was increased in all
patients with CCHF w189.9 (134.8–246.6) nmol/mL/hx.
The median ChT activity in the non-fatal CCHF group
w220.2 (180.6–290.1) nmol/mL/hx was higher compared
with the fatal CCHF group w29.2 (16.5–45.7) nmol/mL/hx
(p-0.001). In univariate analysis, platelet count, lac-
tate dehydrogenase (LDH), and activated partial
thromboplastin time were associated with mortality.
Conclusions: This is the first study investigating the
association of serum ChT enzyme activity with mor-
tality from CCHF. This study suggested that relatively
low ChT enzyme activities may be a prognostic mark-
er in patients with CCHF.
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Introduction
Crimean-Congo hemorrhagic fever (CCHF) was first
described clinically in 1944 in Crimea of the former
Soviet Union during a large outbreak of over 200 cas-
es. The CCHF virus, belonging to the genus Nairovirus
of Bunyaviridae family), was identified in 1967 from a
patient in Uzbekistan, and was found to be similar to
a virus isolated in 1956 in Congo, and therefore,
named Crimean-Congo (1). The virus is transmitted to
humans through the bite of Ixodid ticks or by contact
with blood or tissues from infected livestock (2). CCHF
is not highly contagious. However, there is a risk for
spread from person to person by exposure to infected
blood, respiratory secretions and excreta, resulting
occasionally in nosocomial outbreaks (3).
CCHF is potentially fatal and found in more than 30
countries in Africa, Asia, southeast Europe, and the
Middle East (4, 5). The virus infects the reticuloendo-
thelial system leading to a sudden onset of symp-
toms. Shock and increased vascular permeability are
probably a consequence of hyperactivation of the
cytokine pathways (6). Hemorrhagic complications
may also be related to hepatic damage and coagulo-
pathy (7).
In humans, infection with tickborne CCHF virus
often results in a serious illness followed by death. It
has been estimated that one-third of patients hospi-
talized with CCHF die, although many recover rapidly
after a febrile illness (4). After a brief incubation peri-
od, the patient has sudden onset of fever, myalgia,
nausea and severe headache. Within 3–6 days of the
onset of illness, development of a petechial rash and
hemorrhagic symptoms, such as epistaxis, hemate-
mesis, and melena may occur. The most extremely ill
patients develop multiorgan failure characterized by
shock, hemorrhage and coma (8). Mortality rates
range from 15% to 60% (5).
The pathogenesis of CCHF is not well understood.
The vascular endothelium is both a direct and indirect
target of all hemorrhagic viruses. Mononuclear phag-
ocytes are also targets for hemorrhagic viruses. They
are activated upon infection and release certain cyto-
kines and chemokines. These mediators indirectly
target the endothelium. Serum concentrations of
proinflammatory cytokines including interleukin (IL)-6
and tumor necrosis factor-a (TNF-a) were higher in
patients with fatal CCHF (9).
Chitin is an unbranched polymer formed by b-1,4-
linked N-acetyl-D-glucosamine units found in insects,
fungi and egg shells of some nematodes; it is not
thought to occur in mammals. Catabolism of chitin
is mediated by chitinases (O-glycosyl hydrolases
(EC 3.2.1.-). Mammalian chitinases are all related to
Family 18 chitinases, with Family 19 chitinases found
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primarily in plants. Chitotriosidase (ChT), also known
as macrophage chitinase, is not expressed in mono-
cytes, but is synthesized by activated macrophages in
a number of pathological settings (10, 11). It has abil-
ity to cleave chitotriose, the trimeric form of b-1,4-N-
acetyl-D-glucosamine (12), and is able to catalyze the
hydrolysis of chitin-like substrates, such as 4-methy-
lumbelliferyl chitotrioside (13). It was recently report-
ed that leukocytes may also secrete plasma ChT
under physiological conditions (14). It is secreted pre-
dominantly into blood, and ChT activity is an estab-
lished biochemical marker of macrophage accumula-
tion in several lysosomal diseases, especially Gau-
cher’s disease (10, 11). The function of ChT in humans
is unknown. Approximately 6% of European Cauca-
sians are deficient in ChT activity due to a common
24-base pair duplication in exon 10 of the ChT gene.
No clinical abnormality has been associated with this
genetic defect (15).
The goal of this study was to assess the relationship
between serum ChT activity with mortality due to
CCHF.
Materials and methods
Study design and subjects
We studied 38 patients with non-fatal CCHF (14 females and
24 males), and eight patients (4 females and 4 males) with
fatal CCHF admitted to The Ankara Numune Education and
Research Hospital (ANERH) during the spring and summer
of 2006. All patients with positive IgM and/or PCR results for
CCHF virus in blood participated in the study.
For all patients, only CCHF virus was found as the causa-
tive agent. Analyses for other infectious agents were nega-
tive, including Leptospira, Salmonella, Rickettsia, Brucella,
and Toxoplasma species, Coxiella burnetii, agents of Lyme
disease and malaria, rubella and herpes viruses, cytomega-
lovirus, hepatitis A, B and C viruses. Thirty-six healthy con-
trols (15 females and 21 males) with no clinical evidence of
CCHF were also included. All patients were given supportive
treatment only, including erythrocytes, fresh frozen plasma
and whole blood preparations, depending on the state of
their hemostasis. Following admission to the hospital, anti-
biotics, such as doxycycline and ciprofloxacin were given for
empirical treatment of common regional zoonotic diseases.
The study protocol was approved by the Ethical Committee
of the Ankara Numune Education and Research Hospital,
Ankara, Turkey. Written informed consent was obtained
from patients or their family members and control subjects.
Samples
Serum was collected on the first day and last day (day of
death for fatal CCHF or discharge day for non-fatal CCHF) of
hospitalization for each patient. All sera were stored at –808C
until analysis.
Age, gender, duration of symptoms, history of tick bites,
presence of fever, myalgia, bleeding, white blood cell (WBC)
count, platelet count, alanine aminotransferase (ALT), aspar-
tate aminotransferase (AST), lactate dehydrogenase (LDH),
creatine kinase (CK), prothrombin time (PT), international
normalized ratio (INR), activated partial thromboplastin time
(aPTT) and fibrinogen, measured on the first day of hospi-
talization, were recorded. Serum ChT activity on the first day
of hospitalization in patients with CCHF was compared with
serum ChT activity in healthy controls. We also compared
serum ChT activities and other clinical and laboratory para-
meters in the two groups of patients with non-fatal and fatal
CCHF.
ChT enzyme assay
Analyses for serum ChT enzyme activity were performed
according to the method described by Tunc et al. (16). Brief-
ly, 25 mL of serum was incubated with 100 mL of 22 mmol/L
4-methylumbelliferyl-b-D-N,N,N-triacetylchitotriose in McIl-
vain’s phosphate-citrate buffer, pH: 5.2, for 1 h at 378C.
The reaction was terminated by the addition of 120 mL
0.5 mol/L Na2CO3-NaHCO3 buffer, pH: 10.7, and the fluores-
cence of 4-methylumbelliferone was measured using a
Microfluor 2 fluorimeter (Bio-Tek Instruments, Neufahrn,
Germany; excitation: 355 nm, emission: 460 nm). Serum ChT
activities were expressed as nanomoles of substrate hydro-
lyzed per milliliter per hour (nmol/mL/h). Serum ChT activi-
ties were measured in duplicate. The coefficient of variation
was -5%.
Statistical analysis
Results were presented as medians winterquartiles (25%–
75%)x, frequency, and percent. Groups were compared using
the x2-test and Mann-Whitney U-test. Univariate and multi-
variate logistic regression analyses were used to determine
variables associated with mortality. Statistical analysis was
performed using SPSS 11.5 Statistical Package Program for
Windows (SPSS Inc, Chicago, IL, USA). Differences were
considered significant at p-0.05.
Results
We identified one patient with ChT deficiency in
patients with fatal CCHF. Clinical and laboratory fea-
tures for 46 CCHF patients are summarized in Table
1. Eight of the subjects died as a result of CCHF (fatal
CCHF group). Thirty-eight cases survived (non-fatal
CCHF group). There were significant differences
between non-fatal and fatal CCHF groups with respect
to bleeding, serum ChT activity, platelet count, AST,
LDH, CK, PT and aPTT. However, no significant differ-
ences were noted with respect to age, mean duration
of symptoms, history of tick bites, fever, myalgia,
WBC count, ALT, INR and fibrinogen. AST, LDH, CK,
PT and aPTT were significantly higher in the fatal
CCHF group compared with the non-fatal CCHF group.
Serum ChT activity and platelet count were signifi-
cantly lower in the fatal CCHF group compared with
the non-fatal CCHF group.
ChT activity increased in all patients with CCHF on
the first day of hospitalization (G9.0 nmol/mL/h),
showing a median concentration of 189.9 (134.8–
246.6) nmol/mL/h. The median ChT activity in healthy
blood donors was 159.4 (113.4–208.2) nmol/mL/h and
the median activity of ChT in the fatal CCHF group
was 29.2 (16.5–45.7) nmol/mL/h. Thus, the median
activity of ChT in the control group exceeded that in
the fatal CCHF group by ;5-fold (p-0.001).
The median ChT activity in the non-fatal CCHF
group w220.2 (180.6–290.1) nmol/mL/hx was ;7-fold
Kurt et al.: Chitotriosidase activity in Crimean-Congo hemorrhagic fever 1545
Article in press - uncorrected proof
Table 1 Comparison of demographic, clinical characteristics and laboratory test data between patients with non-fatal CCHF
and fatal CCHF.
Groups p-Value
Non-fatal CCHF Fatal CCHF
n 38 8
Male, n 24 (63.2%) 4 (50%) 0.693
Age, years 42.5 (34–61) 61 (50–69) 0.074
Mean duration of symptoms, days 7 (5.0–8.25) 4.5 (3.25–9.0) 0.231
Tick-bite history, n (%) 22 (57.9%) 6 (75%) 0.453
Fever, n 34 (84.5%) 7 (87.5%) 0.870
Myalgia, n 35 (92.1%) 8 (100%) 1.000
Bleeding, n 10 (26.3%) 8 (100%) -0.001
Chitotriosidase activitya, nmol/mL/h 220.2 (180.6–290.1) 29.2 (16.5–45.7) -0.001
Chitotriosidase activityb, nmol/mL/h 261.8 (204.5–377.5) 33.5 (20.5–47.7) -0.001
WBC counta, =109/L 2.2 (1.5–3.3) 2.3 (1.6–3.7) 0.650
Platelet counta, =109/L 76.5 (26.5–105.5) 15.0 (6.3–34.5) 0.003
ASTa, U/L 202.5 (70–541) 780.5 (478–1060) 0.002
ALTa, U/L 90 (52–258) 220 (131–251) 0.080
LDHa, U/L 501.5 (343–789) 1587 (1158–3768) -0.001
CKa, U/L 238 (130–803) 1148 (472–2165) 0.049
PTa, s 120 (112–131) 143.5 (123–147) 0.025
INRa 0.95 (0.87–1.04) 1.13 (0.93–1.21) 0.072
aPTTa, s 31.1 (28.4–36.9) 48.7 (41.8–82.0) 0.006
Fibrinogena, mmol/L 2.45 (2.29–3.31) 2.50 (1.69–3.06) 0.794
Data are number (%) of patients or median winterquartiles (25%–75%)x. aOn the first day of admission to the hospital. bOn the
last day of admission to the hospital. CCHF, Crimean-Congo hemorrhagic fever; WBC, white blood cell; AST, aspartate ami-
notransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK, creatine kinase; PT, prothrombin time; INR,
international normalized ratio; aPTT, activated partial thromboplastin time.
Figure 1 Serum chitotriosidase activities in non-fatal and
fatal CCHF patients compared to control subjects.
higher compared with the fatal CCHF group w29.2
(16.5–45.7) nmol/mL/hx (Figure 1). The difference
between the fatal and non-fatal CCHF groups was sta-
tistically significant (p-0.001). The median activities
of ChT on the final day of hospitalization in the non-
fatal CCHF group w261.8 (204.5–377.5) nmol/mL/hx
were significantly higher than those seen in the fatal
CCHF group w33.5 (20.5–47.7) nmol/mL/hx (p-0.001).
The mortality rate was 17.3%. Fatal cases were hos-
pitalized a mean of 4.5 days (range 2–15) prior to
death. The duration of hospitalization was ;7 days
(range 2–24) in non-fatal cases.
Other parameters analyzed for mortality are shown
in Table 2. In univariate analysis, platelet count, LDH
and aPTT were associated with mortality (Table 2).
However, in multivariate analysis none of the
variables was associated with mortality.
Discussion
Chitinases are ubiquitous chitin fragmenting enzymes
present in various organisms and involved in several
biological processes including defense against chitin
containing pathogens, such as fungi. Human ChT is a
fully active chitinase (17). It is now known that acti-
vated macrophages are the main source of ChT. The
ChT enzyme can be considered an inflammatory pro-
tein since is only secreted by activated macrophages.
It does not behave as an acute reactive protein but
rather as a marker of chronic inflammation (18).
This enzyme is involved in the degradation of chitin
containing pathogens. Little is known about physio-
logical role of ChT and the mechanisms that could
modify its activity in humans, but these might be rel-
evant in clinical practice. High serum ChT activity in
patients with atherosclerosis demonstrates in vivo the
presence of activated macrophages (10).
The activating factors are still unknown, and are
likely to be different in the disorders studied. Increas-
es have been observed in various lysosomal disor-
ders, such as malaria, thalassemia and fungal
infections (19–23). In addition, increased activity has
been reported in tissues and plasma of guinea pigs
infected by Aspergillus fumigates, and in plasma and
urine of a neonate with C. albicans infection (23, 24).
As increased activities of ChT have been described in
neonates with bacterial infections (17), this may sug-
gest that the spectrum of anti-microbial action of ChT
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Table 2 Univariate analysis of risk factors for mortality of patients with CCHF.
OR 95% CI p-Value
Fever 0.82 0.08–8.53 0.87
Myalgia NA NA NA
Bleeding NA NA NA
Tick-bite history 2.18 0.39–12.35 0.38
Chitotriosidase activitya, nmol/mL/h 0.887 0768–1.024 0.103
WBC counta 1.00 1.00–1.001 0.36
Platelet counta 0.95 0.92–0.99 0.02
ASTa 1.001 1.000–1.002 0.06
ALTa 1.000 0.998–1.003 0.84
LDHa 1.003 1.001–1.005 0.01
CKa 1.000 1.000–1.001 0.18
PTa 1.038 0.997–1.081 0.07
INRa 1.035 0.999–1.081 0.13
aPTTa 1.005 1.001–1.009 0.02
Fibrinogena 0.998 0.988–1.007 0.63
aOn the first day of admission to the hospital. CCHF, Crimean-Congo hemorrhagic fever; OR, odds ratio; NA, non-applicable;
WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase; LDH, lactate dehydrogenase; CK,
creatine kinase; PT, prothrombin time; INR, international normalized ratio; aPTT, activated partial thromboplastin time.
extends to bacteria, thus playing a complementary
role to lysozyme. Lysozyme has a well-documented
action against bacteria but less is known about its
anti-fungal activity (25, 26). However, data from
another study do not support this view (12).
To our knowledge, there is no information concern-
ing the association between serum ChT activity with
CCHF. Our study is the first clinical study to assess
this relationship in patients with CCHF, as well as
being the first study to investigate the association of
serum ChT activity with mortality from CCHF.
In the studies analyzing risk factors in patients with
CCHF, parameters during the first 5 days of illness
were studied (27). However, we used parameters
measured on the first day of admission to predict
mortality. Bakir et al. reported that INR, AST, LDH, and
CK were higher in patients who died (28). In their
study, serum ChT activities were significantly lower
in patients with fatal CCHF compared with non-fatal
CCHF and healthy controls. Serum ChT could be a
prognostic marker in patients with CCHF. Different
predictors of fatality were reported as risk factors for
CCHF (27, 29–32), and those previously defined sever-
ity criteria were not always consistent. These criteria
include decreased platelet counts, prolonged aPTT,
increased AST, ALT and LDH activities in a univariate
analysis from five different studies. As ANERH is a
referral and tertiary-care hospital, more complicated
cases are transferred to this facility from other hos-
pitals. The overall mortality rate of CCHF disease was
17.3% in this study. Our mortality rate is higher than
the average for Turkey (5.4%) (32). In the current
study, decreased platelet counts, increased LDH and
prolonged aPTT were identified as predictors of mor-
tality in univariate analysis. However, in multivariate
analysis, none of the variables was found to be sta-
tistically significant. This may be due to the limited
numbers of fatal CCHF cases.
In conclusion, the present study suggested that rel-
atively low ChT enzyme activity may be a prognostic
marker in patients with CCHF. This is the first study
investigating the association of serum ChT enzyme
activity with mortality in CCHF. In this study, we
report that low serum ChT enzyme activity can be
detected in patients with fatal CCHF. In addition, we
detected high and normal serum ChT activities in
patients with non-fatal CCHF. This finding suggests
that ChT may have an antiviral feature or a protective
effect against secondary bacterial infections during
CCHF. Further studies with larger numbers of patients
are required to clarify this hypothesis and to confirm
these promising but preliminary results.
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